Risperidone Long-Acting Injectable (Lai) Suspension
Form: Long-acting injectable (LAI) suspension
Strength: 25 mg, 37.5 mg, 50 mg per dose
Reference Brands: Risperdal®(US & EU); EU: Risperidon-ratiopharm®, Rispolept®, Rispen®
Category: Antipsychotropic Drugs
Risperidone Long-Acting Injectable (LAI) suspension is approved by the FDA in the United States and the EMA in the European Union for the treatment of schizophrenia and maintenance therapy in bipolar I disorder. It offers an extended-release formulation designed for intramuscular injection every two weeks or monthly, ensuring steady therapeutic levels and improving medication adherence. Regulatory bodies emphasize its importance in reducing relapse rates and hospitalizations. Prescribers must adhere to initiation protocols, especially when transitioning from oral risperidone. To explore additional forms and strengths of risperidone LAI, visit Pharmatradz.com.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Risperidone Long-Acting Injection
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Form: Long-Acting Injection
Reference Brands: Risperdal Consta(US &EU)
View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)
Strength: 200 mg/mL, 500 mg/mL
Form: Long-acting IM Injection (Depot)
Reference Brands: Clopixol Depot®(US)
View Details
Zuclopenthixol Short-Acting Intramuscular Injection
Strength: 50 mg/mL
Form: Short-acting Intramuscular Injection
Reference Brands: Clopixol-Acuphase®
View Details
Zuclopenthixol Tablets
Strength: 10 mg, 25 mg, 40 mg
Form: Oral Tablets
Reference Brands: Clopixol®(EU)
View Details